Status:
UNKNOWN
Single Dose of Tranexamic Acid and Blood Loss, in Elderly Patients With Hip Fracture
Lead Sponsor:
National and Kapodistrian University of Athens
Conditions:
Blood Loss, Surgical
Hip Fractures
Eligibility:
All Genders
75+ years
Phase:
PHASE2
Brief Summary
The aim of this study is to investigate the hypothesis that single dose of tranexamic acid (TXA) preoperatively will lower blood loss and transfusion rate in elderly patients with hip fractures (inter...
Eligibility Criteria
Inclusion
- Consecutive elderly patients (age \>75 yo) undergoing hip fracture surgery for a stable or unstable intertrochanteric hip fracture with the insertion of a short intramedullary nail (IMN) as well as patients treated surgically with cemented hemiarthroplasty for acute femoral neck (subcapital) hip fracture.
Exclusion
- Any contraindication for tranexamic acid
- Multiple fractures
- Requirement for anticoagulant therapy that could not be stopped.
- Ongoing thromboembolic event
- reduced kidney function
- malignancy,
- pathological fracture
- previous operation on the affected hip
- Active coronary artery disease (event in the past 12 months).
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2018
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03251469
Start Date
January 1 2013
End Date
February 1 2018
Last Update
August 16 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
2nd Department of Orthopaedics
Athens, Attica, Greece, 14233